These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 29425306)
1. Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. Yurdaydin C; Keskin O; Kalkan Ç; Karakaya F; Çaliskan A; Kabaçam G; Önder FO; Karatayli S; Karatayli E; Deda X; Bozkaya H; Bozdayi AM; Idilman R J Infect Dis; 2018 Mar; 217(8):1184-1192. PubMed ID: 29425306 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study. Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydın E; Onel D; Gulluoglu M; Karaca C; Akyuz F; Demir K; Besisik F; Kaymakoglu S Postgrad Med; 2016 May; 128(4):432-8. PubMed ID: 27054544 [TBL] [Abstract][Full Text] [Related]
3. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319 [TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring. Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028 [TBL] [Abstract][Full Text] [Related]
5. Therapy of Delta Hepatitis. Yurdaydin C; Idilman R Cold Spring Harb Perspect Med; 2015 Aug; 5(10):. PubMed ID: 26253093 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528 [TBL] [Abstract][Full Text] [Related]
7. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Gunsar F; Akarca US; Ersoz G; Kobak AC; Karasu Z; Yuce G; Ilter T; Batur Y Antivir Ther; 2005; 10(6):721-6. PubMed ID: 16218171 [TBL] [Abstract][Full Text] [Related]
9. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline]. Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887 [TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Kabaçam G; Dalekos GN; Çakaloğlu Y; Zachou K; Bock T; Erhardt A; Zeuzem S; Tabak F; Yalçin K; Bozdayi AM; Dienes HP; Bozkaya H; Manns M; Wedemeyer H; Yurdaydin C Turk J Gastroenterol; 2012; 23(5):560-8. PubMed ID: 23161302 [TBL] [Abstract][Full Text] [Related]
11. [Discussions the therapy strategy of chronic hepatitis B by analyzing the therapeutics course of a chronic hepatitis B patient]. Yang LQ Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):709-10. PubMed ID: 19785967 [No Abstract] [Full Text] [Related]
12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule]. Horváth G; Tolvaj G; Halász T; Stotz G Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients. Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377 [TBL] [Abstract][Full Text] [Related]